* Osmotica Pharmaceuticals PLC OSMT.OQ OSMT.O is expected
to show a fall in quarterly revenue when it reports results on
November 11.
* The Bridgewater, New Jersey-based company is expected to
report a 95.9% decrease in revenue to $2.358 million from
$57.17 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Osmotica
Pharmaceuticals PLC is for a loss of 31 cents per share. For the
same quarter last year, the company reported a loss of 14 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Osmotica
Pharmaceuticals PLC is $6, about 67.2% above its last closing
price of $1.97.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2021 -0.14 -0.14 -0.28 Missed -100
Mar. 31 2021 -0.23 -0.23 -0.15 Beat 36.2
Dec. 31 2020 -0.28 -0.24 -0.88 Missed -271.8
Sep. 30 2020 -0.20 -0.20 -0.14 Beat 30
Jun. -0.12 -0.12 -0.22 Missed -76
30 2020
Mar. 31 2020 -0.15 -0.14 -0.05 Beat 65.1
Dec. 31 2019 -0.09 -0.06 -0.51 Missed -696.9
Sep. 30 2019 -0.23 -0.20 -2.15 Missed -961.7
This summary was machine generated November 12 at 23:07 GMT.
All figures in US dollars unless otherwise stated